• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 31, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Rheumatology leaders say FDA biosimilar interchangeability guidance a balanced approach

Bioengineer by Bioengineer
January 18, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ATLANTA – The Food and Drug Administration (FDA) has released a draft guidance on biosimilar interchangeability titled "Considerations in Demonstrating Interchangeability With a Reference Product" that leaders at the American College of Rheumatology (ACR) believe may address many of the safety and efficacy concerns physicians have raised over the past year.

"The ACR is pleased to see the FDA issue draft guidance on biosimilar interchangeability," expressed Dr. Angus Worthing, MD, FACP, chair of the ACR's Government Affairs Committee. "This guidance brings us one step closer to the shared goal of lowering prices in the biologics marketplace. While the ACR is still reviewing the document and will provide detailed comments to the FDA in the coming weeks, our initial reaction is that the draft guidance strikes a good balance between ensuring safety and efficacy while also getting biosimilar products to market as efficiently as possible."

"We also applaud the FDA for suggesting clinical studies which switch back and forth, not just one-way from the reference drug to the biosimilar. The use of at least two exposure periods to each drug will mimic to some extent what our patients are likely to experience with changing formularies in a multi-payer, multi-state, ever-changing market."

###

See the full text of the draft guidance here. The ACR plans to submit detailed comments on the guidance in the coming weeks.

The American College of Rheumatology (ACR) is the nation's leading advocacy organization for the rheumatology care community, representing more than 6,400 U.S. rheumatologists and rheumatology health professionals. As an ethically driven, professional membership organization committed to improving healthcare for Americans living with rheumatic diseases, the ACR advocates for high-quality, high-value policies and reforms that will ensure safe, effective, affordable and accessible rheumatology care.

Media Contact

Jocelyn Givens
[email protected]
@ACRheum

http://www.rheumatology.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

August 31, 2026
Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

August 31, 2026

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

August 31, 2026

Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

August 31, 2026
Please login to join discussion

POPULAR NEWS

  • β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

    29 shares
    Share 12 Tweet 7
  • Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

    29 shares
    Share 12 Tweet 7
  • KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

    29 shares
    Share 12 Tweet 7
  • Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.